Last updated on July 2018

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Brief description of study

This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.

Clinical Study Identifier: NCT01359969

Contact Investigators or Research Sites near you

Start Over

Vaclava Gutova, Dr.

UIA FN Plzen ( Institute of Immunology and Allergology), Faculty Hospital Plzen
Plzen, Czech Republic

Radana Zachova, Dr.

University Hospital Motol, Institute of Immunology
Prague, Czech Republic